TIDMNMC

RNS Number : 8478J

NMC Health Plc

22 August 2019

22 August 2019

NMC Health plc

(the "Company" or "NMC")

Share buyback programme

NMC Health plc ("NMC" or the "Company") announces that it intends to immediately initiate the process to seek shareholder approval for a share buyback programme. The buyback authority will require formal approval by shareholders at a General Meeting.

As the leading shareholders in the Company have indicated that they would not be willing to participate in any buyback at the Company's present valuation, the Company will be required to also seek shareholder approval to waive the compulsory purchase provisions as stated in Rule 9 of the Takeover Code.

The Company has a number of very attractive investment opportunities for the short and medium term which it remains committed to deliver. Further, the Company also maintains a strong balance sheet to provide suitable optionality of funding and therefore the share buyback programme will, subject to shareholder approval, only be employed opportunistically to take advantage of exceptional price volatility and will be limited to a maximum of US$200m.

Shareholders will be kept informed of the timetable for the proposed shareholder vote and the publication of the accompanying shareholder circular.

Contacts

 
 NMC 
 Asjad Yahya, Investor Relations              +971 (0)56 219 0975 
 
 Media 
 FTI Consulting, London 
 Brett Pollard / Victoria Foster Mitchell/ 
  Mary Whittow                                +44 (0)20 3727 1000 
 
 FTI Consulting, Gulf 
 Shane Dolan                                  +971 (0)4 437 2100

About NMC Health

NMC is the leading private healthcare operator in the GCC with an international network of healthcare facilities across 19 countries. NMC ranks as one of the top two in-vitro fertilisation ("IVF") operators globally. The Group is recognised as a leading provider of long-term medical care in the UAE through its subsidiary ProVita. Pursing a selective international expansion program since 2016, the company now has total capacity of 3,109 beds across its network with 48% of this capacity in the Kingdom of Saudi Arabia (KSA), where the company has introduced long-term and multi-specialty care services. Moreover, the recent formation of a joint venture with GOSI/Hassana Investment Company provides a solid platform for continued growth in the GCC region's largest healthcare market. NMC treated over 7.5m patients in 2018. The Group is also a leading UAE supplier of products and consumables across several key market segments, with the major contribution coming from healthcare related products. The Group reported revenues of US$2.1 billion for the year ended 31 December 2018.

In April 2012 NMC was listed on the Premium Segment of the London Stock Exchange. NMC is a constituent of the FTSE 100 Index.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

MSCFMGZRGMGGLZZ

(END) Dow Jones Newswires

August 22, 2019 02:02 ET (06:02 GMT)

Nmc Health (LSE:NMC)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024 Haga Click aquí para más Gráficas Nmc Health.
Nmc Health (LSE:NMC)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024 Haga Click aquí para más Gráficas Nmc Health.